Psoriatic arthritis for dermatologists

References

• Acosta Felquer ML, FitzGerald O. Peripheral joint involvement in psoriatic arthritis patients. Clin Exp Rheumatol. 2015;33:S26–S30.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69:729–735.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3:91–102.
   PubMed Web of Science ®Google Scholar
• Coates LC, Hodgson R, Conaghan PG, et al. MRI and ultrasonography for diagnosis and monitoring of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2012;26:805–822.
   PubMed Web of Science ®Google Scholar
• Terslev L, Naredo E, Iagnocco A, et al. Defining enthesitis in spondyloarthritis by ultrasound: results of a Delphi process and of a reliability reading exercise. Arthritis Care Res. 2014;66:741–748.
   PubMed Web of Science ®Google Scholar
• Gladman DD. Clinical features and diagnostic considerations in psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:569–579.
   PubMed Web of Science ®Google Scholar
• Polachek A, Li S, Chandran V, et al. Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome. Arthritis Care Res. 2017;69:1685–1691.
   PubMed Web of Science ®Google Scholar
• Liu JT, Yeh HM, Liu SY, et al. Psoriatic arthritis: epidemiology, diagnosis, and treatment. WJO. 2014;5:537–543.
   Google Scholar
• Cohen JM, Husni ME, Qureshi AA, et al. Psoriatic arthritis: it’s as easy as “PSA”. J Am Acad Dermatol. 2015;72:905–906.
   PubMed Web of Science ®Google Scholar
• Eder L, Chandran V, Gladman DD. What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis? Curr Opin Rheumatol. 2015;27:91–98.
   PubMed Web of Science ®Google Scholar
• Eder L, Chandran V, Pellet F, et al. Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis. 2012;71:50–55.
   PubMed Web of Science ®Google Scholar
• Rahman P, Roslin NM, Pellett FJ, et al. High resolution mapping in the major histocompatibility complex region identifies multiple independent novel loci for psoriatic arthritis. Ann Rheum Dis. 2011;70:690–694.
   PubMed Web of Science ®Google Scholar
• Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–970.
   PubMed Web of Science ®Google Scholar
• FitzGerald O, Haroon M, Giles JT, et al. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015;17:115.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Cheung C, Ng CM, et al. HLA-C locus alleles in patients with psoriatic arthritis (PsA). Hum Immunol. 1999;60:259–261.
   PubMed Web of Science ®Google Scholar
• Chandran V, Schentag CT, Brockbank JE, et al. Familial aggregation of psoriatic arthritis. Ann Rheum Dis. 2009;68:664–667.
   PubMed Web of Science ®Google Scholar
• Karason A, Love TJ, Gudbjornsson B. A strong heritability of psoriatic arthritis over four generations—the Reykjavik Psoriatic Arthritis Study. Rheumatology. 2009;48:1424–1428.
   PubMed Web of Science ®Google Scholar
• Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther. 2009;11:214.
   PubMed Web of Science ®Google Scholar
• Suzuki E, Mellins ED, Gershwin ME, et al. The IL-23/IL-17 axis in psoriatic arthritis. Autoimmun Rev. 2014;13:496–502.
   PubMed Web of Science ®Google Scholar
• Lebwohl MG, Kavanaugh A, Armstrong AW, et al. US Perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Am J Clin Dermatol. 2016;17:87–97.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:ii14–ii17.
   PubMed Web of Science ®Google Scholar
• Catanoso M, Pipitone N, Salvarani C. Epidemiology of psoriatic arthritis. Reumatismo. 2012;64:66–70.
   PubMedGoogle Scholar
• Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the experience diagnosing, understanding care, and treatment with etanercept (EDUCATE) study. J Dermatolog Treat. 2006;17:343–352.
   PubMed Web of Science ®Google Scholar
• Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken). 2011;63:1729–1735.
   PubMed Web of Science ®Google Scholar
• de Oliveira M, de Oliveira Rocha B, Vieira Duarte G. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90:9–20.
   PubMed Web of Science ®Google Scholar
• Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–864.
   PubMed Web of Science ®Google Scholar
• Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045–1050.
   PubMed Web of Science ®Google Scholar
• Gladman DD. Recent advances in understanding and managing psoriatic arthritis. F1000Res. 2016;5:2670.
   PubMedGoogle Scholar
• Kavanaugh A, Ritchlin C, Rahman P, et al. Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PSUMMIT-2 trials. Ann Rheum Dis. 2014;73:1000–1006.
   PubMed Web of Science ®Google Scholar
• Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47:29–37.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Distinguishing inflammatory from noninflammatory arthritis, enthesitis, and dactylitis in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol. 2012;39:415–417.
   PubMedGoogle Scholar
• Punzi L, Podswiadek M, Oliviero F, et al. Laboratory findings in psoriatic arthritis. Reumatismo. 2007;59(1):52–55.
   Google Scholar
• Sakkas LI, Alexiou I, Simopoulou T, et al. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum. 2013;43:325–334.
   PubMed Web of Science ®Google Scholar
• Karreman MC, Weel AE, van der Ven M, et al. Prevalence of psoriatic arthritis in primary care patients with psoriasis. Arthritis Rheumatol. 2016;68:924–931.
   PubMedGoogle Scholar
• Almodóvar R, Carmona L, Zarco P, et al. Fibromyalgia in patients with ankylosing spondylitis: prevalence and utility of the measures of activity, function and radiological damage. Clin Exp Rheumatol. 2010;28:S33–S39.
   PubMed Web of Science ®Google Scholar
• Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res. 2010;62:600–610.
   PubMed Web of Science ®Google Scholar
• Marchesoni A, Atzeni F, Spadaro A, et al. Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. J Rheumatol. 2012;39:849–855.
   PubMed Web of Science ®Google Scholar
• Stavropoulos PG, Soura E, Kanelleas A, et al. Reactive arthritis. J Eur Acad Dermatol Venereol. 2015;29:415–424.
   PubMed Web of Science ®Google Scholar
• Cervini C, Leardini G, Mathieu A, et al. Psoriatic arthritis: epidemiological and clinical aspects in a cohort of 1.306 Italian patients. Reumatismo. 2005;57:283–290.
   PubMedGoogle Scholar
• Mensah KA, Schwarz EM, Ritchlin CT. Altered bone remodeling in psoriatic arthritis. Curr Rheumatol Rep. 2008;10:311–317.
   PubMedGoogle Scholar
• McGonagle D, Hermann KG, Tan AL. Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era. Rheumatology. 2015;54:29–38.
   PubMed Web of Science ®Google Scholar
• Brikman S, Furer V, Wollman J, et al. The effect of the presence of fibromyalgia on common clinical disease activity indices in patients with psoriatic arthritis: a cross-sectional study. J Rheumatol. 2016;43:1749–1754.
   PubMed Web of Science ®Google Scholar
• Merola JF, Wu S, Han J, et al. Psoriasis, psoriatic arthritis and risk of gout in US men and women. Ann Rheum Dis. 2015;74:1495–1500.
   PubMed Web of Science ®Google Scholar
• Husni ME, Meyer KH, Cohen DS, et al. The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool. J Am Acad Dermatol. 2007;57:581–587.
   PubMed Web of Science ®Google Scholar
• Ibrahim GH, Buch MH, Lawson C, et al. Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire. Clin Exp Rheumatol. 2009;27:469–474.
   PubMed Web of Science ®Google Scholar
• Chandran V, Gladman DD. Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire: a report from the GRAPPA 2009 annual meeting. J Rheumatol. 2011;38:546–547.
   PubMedGoogle Scholar
• Karreman MC, Weel A, van der Ven M, et al. Performance of screening tools for psoriatic arthritis: a cross-sectional study in primary care. Rheumatology. 2017;56:597–602.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Qureshi A, Merola JF, et al. Diagnosing and treating psoriatic arthritis: an update. Br J Dermatol. 2014;170:772–786.
   PubMed Web of Science ®Google Scholar
• Dominguez P, Gladman DD, Helliwell P, et al. Development of screening tools to identify psoriatic arthritis. Curr Rheumatol Rep. 2010;12:295–299.
   PubMedGoogle Scholar
• Walsh JA, Callis Duffin K, Krueger GG, et al. Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis. J Rheumatol. 2013;40:287–293.
   PubMed Web of Science ®Google Scholar
• Merola JF, Husni ME, Qureshi AA. Screening instruments for psoriatic arthritis. J Rheumatol. 2013;40:1623.
   PubMed Web of Science ®Google Scholar
• Husni ME, Qureshi AA, Koenig AS, et al. Utility of the PASE questionnaire, psoriatic arthritis (PsA) prevalence and PsA improvement with anti-TNF therapy: results from the PRISTINE trial. J Dermatolog Treat. 2014;25:90–95.
   PubMed Web of Science ®Google Scholar
• Coates LC, Aslam T, Al Balushi F, et al. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study). Br J Dermatol. 2013;168:802–807.
   PubMed Web of Science ®Google Scholar
• Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665–2673.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Armstrong AW. Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs. 2014;74:423–441.
   PubMed Web of Science ®Google Scholar
• Mease PJ. Measures of psoriatic arthritis: tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthr Care Res. 2011;63:S64–S85.
   PubMed Web of Science ®Google Scholar
• Strand V, Singh JA. Evaluation and management of the patient with suspected inflammatory spine disease. Mayo Clin Proc. 2017;92:555–564.
   PubMed Web of Science ®Google Scholar
• Golder V, Schachna L. Ankylosing spondylitis: an update. Aust Fam Physician. 2013;42:780–784.
   PubMedGoogle Scholar
• Brockbank JE, Stein M, Schentag CT, et al. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64:188–190.
   PubMed Web of Science ®Google Scholar
• Kaeley GS, Eder L, Aydin SZ, et al. Dactylitis: a hallmark of psoriatic arthritis. Semin Arthritis Rheum. 2018;48:263–273.
   PubMed Web of Science ®Google Scholar
• Rothschild BM, Pingitore C, Eaton M. Dactylitis: implications for clinical practice. Semin Arthritis Rheum. 1998;28:41–47.
   PubMed Web of Science ®Google Scholar
• Olivieri I, Padula A, Scarano E, et al. Dactylitis or “sausage-shaped” digit. J Rheumatol. 2007;34:1217–1222.
   PubMed Web of Science ®Google Scholar
• Falkenburg WJ, van Schaardenburg D, Ooijevaar-de Heer P, et al. IgG subclass specificity discriminates restricted IgM rheumatoid factor responses from more mature anti-citrullinated protein antibody-associated or isotype-switched IgA responses. Arthritis Rheumatol. 2015;67:3124–3134.
   PubMed Web of Science ®Google Scholar
• Waller M, Toone EC, Vaughan E. Study of rheumatoid factor in a normal population. Arthritis Rheum. 1964;7:513–520.
   PubMed Web of Science ®Google Scholar
• Inanc N, Dalkilic E, Kamali S, et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol. 2007;26:17–23.
   PubMed Web of Science ®Google Scholar
• Candia L, Marquez J, Gonzalez C, et al. Low frequency of anticyclic citrullinated peptide antibodies in psoriatic arthritis but not in cutaneous psoriasis. J Clin Rheumatol. 2006;12:226–229.
   PubMed Web of Science ®Google Scholar
• Popescu C, Zofotă S, Bojincă V, et al. Anti-cyclic citrullinated peptide antibodies in psoriatic arthritis—cross-sectional study and literature review. J Med Life. 2013;6:376–382.
   PubMedGoogle Scholar
• Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61:233–239.
   PubMed Web of Science ®Google Scholar
• Patrizi A, Venturi M, Scorzoni R, et al. Nail dystrophies, scalp and intergluteal/perianal psoriatic lesions: risk factors for psoriatic arthritis in mild skin psoriasis? G Ital Dermatol Venereol. 2014;149:177–184.
   PubMed Web of Science ®Google Scholar
• Takata T, Takahashi A, Taniguchi Y, et al. Detection of asymptomatic enthesitis in psoriasis patients: an onset of psoriatic arthritis? J Dermatol. 2016;43:650–654.
   PubMed Web of Science ®Google Scholar
• Papadavid E, Katsimbri P, Kapniari I, et al. Prevalence of psoriatic arthritis and its correlates among patients with psoriasis in Greece: results from a large retrospective study. J Eur Acad Dermatol Venereol. 2016;30:1749–1752.
   PubMed Web of Science ®Google Scholar
• Merola JF, Li T, Li WQ, et al. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41:486–489.
   PubMed Web of Science ®Google Scholar
• Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis—clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43:790–794.
   PubMed Web of Science ®Google Scholar
• Tan AL, Benjamin M, Toumi H, et al. The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis—a high-resolution MRI and histological study. Rheumatology (Oxford). 2006;46:253–256.
   PubMed Web of Science ®Google Scholar
• Aydin SZ, Castillo-Gallego C, Ash ZR, et al. Ultrasonographic assessment of nail in psoriatic disease shows a link between onychopathy and distal interphalangeal joint extensor tendon enthesopathy. Dermatology. 2012;225:231–235.
   PubMed Web of Science ®Google Scholar
• Tan AL, Grainger AJ, Tanner SF, et al. A high-resolution magnetic resonance imaging study of distal interphalangeal joint arthropathy in psoriatic arthritis and osteoarthritis: are they the same? Arthritis Rheum. 2006;54:1328–1333.
   PubMed Web of Science ®Google Scholar
• McGonagle D. Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. J Eur Acad Dermatol Venereol. 2009;23: 9–13.
   PubMed Web of Science ®Google Scholar
• Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017;55:131–135.
   PubMedGoogle Scholar
• Rouzaud M, Sevrain M, Villani AP, et al. Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J Eur Acad Dermatol Venereol. 2014;28: 17–26.
   PubMed Web of Science ®Google Scholar
• Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68:1060–1071.
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499–510.
   PubMed Web of Science ®Google Scholar
• Perez-Chada LM, Cohen JM, Gottlieb AB, et al. Achieving international consensus on the assessment of psoriatic arthritis in psoriasis clinical trials: an International Dermatology Outcome Measures (IDEOM) initiative. Arch Dermatol Res. 2018;310:701–710.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38:727–735.
   PubMed Web of Science ®Google Scholar
• Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 1993;36:729–740.
   PubMed Web of Science ®Google Scholar
• Clegg DO, Reda DJ, Mejias E, et al. Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of veterans affairs cooperative study. Arthritis Rheum. 1996;39:2013–2020.
   PubMed Web of Science ®Google Scholar
• Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227–1236.
   PubMed Web of Science ®Google Scholar
• Helliwell PS, Firth J, Ibrahim GH, et al. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol. 2005;32:1745–1750.
   PubMed Web of Science ®Google Scholar
• Ferguson EG, Coates LC. Optimisation of rheumatology indices: dactylitis and enthesitis in psoriatic arthritis. Clin Exp Rheumatol. 2014;32:S-113–S-117.
   PubMed Web of Science ®Google Scholar
• Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. Arthritis Rheum. 2008;59:686–691.
   PubMed Web of Science ®Google Scholar
• Maksymowych WP, Mallon C, Morrow S, et al. Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis index. Ann Rheum Dis. 2009;68:948–953.
   PubMed Web of Science ®Google Scholar
• Langley RG, Feldman SR, Nyirady J, et al. The 5-point Investigator’s Global Assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26:23–31.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Siegel MP, Bagel J, et al. From the medical board of the national psoriasis foundation: treatment targets for plaque psoriasis. J Am Acad Dermatol. 2017;76:290–298.
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Merola JF, Chen R, et al. Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA x BSA) composite tool: an analysis of apremilast phase 3 ESTEEM data. J Am Acad Dermatol. 2017;77:1178–1180.
   PubMed Web of Science ®Google Scholar
• Merola JF, Amato DA, See K, et al. Evaluation of sPGA × BSA as an outcome measure and treatment target for clinical practice. J Invest Dermatol. 2018;138:1955–1961.
   PubMed Web of Science ®Google Scholar
• Walsh JA, McFadden M, Woodcock J, et al. Product of the physician global assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013;69:931–937.
   PubMed Web of Science ®Google Scholar
• Wassenberg S. Radiographic scoring methods in psoriatic arthritis. Clin Exp Rheumatol. 2015;33:S55–S59.
   PubMed Web of Science ®Google Scholar
• Tillett W, Jadon D, Shaddick G, et al. Feasibility, reliability, and sensitivity to change of four radiographic scoring methods in patients with psoriatic arthritis. Arthritis Care Res. 2014;66:311–317.
   Web of Science ®Google Scholar
• van der Heijde D, Lassere M, Edmonds J, et al. Minimal clinically important difference in plain films in RA: group discussions, conclusions, and recommendations. OMERACT Imaging Task Force. J Rheumatol. 2001;28:914–917.
   PubMed Web of Science ®Google Scholar
• Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. Arthritis Rheum. 2002;46:913–920.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum. 2007;56:2698–2707.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum. 2012;64:2504–2517.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Husni ME, Harrison DD, et al. Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis: results through week twenty-four of the GO-VIBRANT study. Arthritis Rheumatol. 2017;69:2151–2161.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Gottlieb AB, van der Heijde D, et al. Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. Ann Rheum Dis. 2017;76:1550–1558.
   PubMed Web of Science ®Google Scholar
• Humira (adalimumab) [prescribing information]. North Chicago (IL): AbbVie Inc.; 2018.
   Google Scholar
• Humira [summary of product characteristcs]. Ludwigshafen, Germany: AbbVie Deutschland GmbH & Co. KG.; 2017.
   Google Scholar
• Remicade (infliximab) [prescribing information]. Horsham (PA): Janssen Biotech, Inc.; 2018.
   Google Scholar
• Remicade [summary of product characteristics]. Leiden, The Netherlands: Janssen Biologics B.V.; 2018.
   Google Scholar
• Enbrel (etanercept) [prescribing information]. Thousand Oaks (CA): Immunex Corporation; 2017.
   Google Scholar
• Enbrel [summary of product characteristics]. Kent (UK): Pfizer Limited; 2014.
   Google Scholar
• Cimzia (certolizumab pegol) [prescribing information]. Smyrna (GA): UCB, Inc.; 2017.
   Google Scholar
• Cimzia [summary of product characteristics]. Bruxelles, Belgium: UCB Pharma S.A.; 2019.
   Google Scholar
• Taltz (ixekizumab) [prescribing information]. Indianapolis (IN): Eli Lilly and Company; 2018.
   Google Scholar
• Taltz [summary of product characteristics]. Utrecht, The Netherlands: Eli Lilly Nederland B.V.; 2016.
   Google Scholar
• Cosentyx (secukinumab) [prescribing information]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2018.
   Google Scholar
• Cosentyx [summary of product characteristics]. Camberley (UK): Novartis Europharm Limited; 2016.
   Google Scholar
• Orencia (abatacept) [prescribing information]. Princeton (NJ): Bristol-Myers Squibb Company; 2017.
   Google Scholar
• Orencia [summary of product characteristics]. Uxbridge (UK): Bristol-Myers Squibb Pharma EEIG; 2019.
   Google Scholar
• Simponi [summary of product characteristics]. Leiden, The Netherlands: Janssen Biologics B.V.; 2019.
   Google Scholar
• Stelara [summary of product characteristics]. Beerse, Belgium: Janssen-Cilag International NV.; 2016.
   Google Scholar
• Xeljanz [summary of product characteristics]. Kent (UK): Pfizer Limited; 2018.
   Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68: ii1–i44.
   PubMed Web of Science ®Google Scholar
• Toussirot E. Biologics in spondyloarthritis: TNFα inhibitors and other agents. Immunotherapy. 2015;7:669–681.
   PubMed Web of Science ®Google Scholar
• Baeten D, Sieper J, Braun J, et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N Engl J Med. 2015;373:2534–2548.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76:1340–1347.
   PubMed Web of Science ®Google Scholar
• Song IH, Heldmann F, Rudwaleit M, et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis. 2011;70:1108–1110.
   PubMed Web of Science ®Google Scholar
• Chen J, Veras MM, Liu C, et al. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2013;CD004524.
   Web of Science ®Google Scholar
• Mease PJ, Woolley JM, Bitman B, et al. Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction. J Rheumatol. 2011;38:2461–2465.
   PubMed Web of Science ®Google Scholar
• Strand V, Sharp V, Koenig AS, et al. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. Ann Rheum Dis. 2012;71:1143–1150.
   PubMed Web of Science ®Google Scholar
• Gladman D, Fleischmann R, Coteur G, et al. Effect of certolizumab pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study. Arthritis Care Res. 2014;66:1085–1092.
   PubMed Web of Science ®Google Scholar
• Busse JW, Bartlett SJ, Dougados M, et al. Optimal strategies for reporting pain in clinical trials and systematic reviews: recommendations from an OMERACT 12 workshop. J Rheumatol. 2015;42:1962–1970.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476–488.
   PubMed Web of Science ®Google Scholar
• Deodhar A, Gottlieb A, Boehncke WH, et al. OP0218 Efficacy and safety results of guselkumab, and anti-IL23 monoclonal antibody, in patients with active psoriatic arthritis over 24 weeks: a phase 2a, randomized, double-blind, placebo-controlled study [abstract]. Ann Rheum Dis. 2017;76:142–143.
   Google Scholar
• Mease PJ, McInnes IB, Kirkham B, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373:1329–1339.
   PubMed Web of Science ®Google Scholar
• Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017;377:1525–1536.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014;73:1020–1026.
   PubMed Web of Science ®Google Scholar
• Mease PJ, van der Heijde D, Ritchlin CT, et al. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79–87.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264–2272.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Kavanaugh A, Gottlieb AB, et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet. 2013;382:780–789.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Fleischmann R, Deodhar AA, et al. Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2014;73:48–55.
   PubMed Web of Science ®Google Scholar
• Holland R, Tillett W, Korendowych E, et al. Validation of the Psoriatic Arthritis Impact of Disease (PsAID) Questionnaire and its potential as a single-item outcome measure in clinical practice. Ann Rheum Dis. 2018;77:343–347.
   PubMedGoogle Scholar
• Coates LC, Tillett W, Shaddick G, et al. Value of the Routine Assessment of Patient Index Data 3 in patients with psoriatic arthritis: results from a tight-control clinical trial and an observational cohort. Arthritis Care Res. 2018;70:1198–1205.
   Web of Science ®Google Scholar
• Helliwell PS, FitzGerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis. 2013;72:986–991.
   PubMed Web of Science ®Google Scholar
• Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis. 2010;69:48–53.
   PubMed Web of Science ®Google Scholar
• Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386:2489–2498.
   PubMed Web of Science ®Google Scholar
• Taylor PC, Maini RN. Biologic markers in the diagnosis and assessment of rheumatoid arthritis. In: O’Dell JR, editor. UpToDate. Waltham, MA: UpToDate. [cited 28 Nov 2018].
   Google Scholar
• Doherty M, Abhishek A. Clinical manifestations and diagnosis of osteoarthritis. In: Hunter D, editor. UpToDate. Waltham (MA): UpToDate. [cited 28 Nov 2018].
   Google Scholar
• Goldenberg DLG. Clinical manifestations and diagnosis of fibromyalgia in adults. In: Schur PH, editor. UpToDate. Waltham (MA): UpToDate. [cited 28 Nov 2018].
   Google Scholar
• Singh JA. Racial and gender disparities among patients with gout. Curr Rheumatol Rep. 2013;15:307.
   PubMed Web of Science ®Google Scholar
• Rymal E, Rizzolo D. Gout: a comprehensive review. JAAPA. 2014;27:26–31.
   PubMedGoogle Scholar
• Mies Richie A, Francis ML. Diagnostic approach to polyarticular joint pain. Am Fam Physician. 2003;68:1151–1160.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Braun J, Deodhar A, et al. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). Rheumatology. 2013;52:321–325.
   PubMed Web of Science ®Google Scholar
• Rahman P, Gladman DD, Cook RJ, et al. Radiological assessment in psoriatic arthritis. Br J Rheumatol. 1998;37:760–765.
   PubMedGoogle Scholar
• Wassenberg S, Fischer-Kahle V, Herborn G, et al. A method to score radiographic change in psoriatic arthritis. Z Rheumatol. 2001;60:156–166.
   PubMed Web of Science ®Google Scholar
• Mattei PL, Corey KC, Kimball AB. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28:333–337.
   PubMed Web of Science ®Google Scholar
• Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859–866.
   PubMed Web of Science ®Google Scholar
• Ward MM, Guthrie LC, Alba MI. Brief report: rheumatoid arthritis response criteria and patient-reported improvement in arthritis activity: is an American College of Rheumatology twenty percent response meaningful to patients? Arthritis Rheumatol. 2014;66:2339–2343.
   PubMed Web of Science ®Google Scholar
• Zochling J. Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res. 2011;63:S47–S58.
   PubMed Web of Science ®Google Scholar
• Englbrecht M, Wang Y, Ronneberger M, et al. Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives. Arthritis Care Res. 2010;62:977–983.
   Web of Science ®Google Scholar
• Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279–3289.
   PubMed Web of Science ®Google Scholar
• Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 2010;340:c147.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976–986.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–2022.
   PubMed Web of Science ®Google Scholar
• Ortonne JP, Paul C, Berardesca E, et al. A 24-week randomized clinical trial investigating the efficacy and safety of two doses of etanercept in nail psoriasis. Br J Dermatol. 2013;168:1080–1087.
   PubMed Web of Science ®Google Scholar
• Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet. 2005;366:1367–1374.
   PubMed Web of Science ®Google Scholar
• Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106–115.
   PubMed Web of Science ®Google Scholar
• Thaci D, Unnebrink K, Sundaram M, et al. Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. J Eur Acad Dermatol Venereol. 2015;29:353–360.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–1674.
   PubMed Web of Science ®Google Scholar
• Rich P, Bourcier M, Sofen H, et al. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1. Br J Dermatol. 2014;170:398–407.
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326–338.
   PubMed Web of Science ®Google Scholar
• Reich K, Arenberger P, Mrowietz U, et al. Secukinumab shows high and sustained efficacy in nail psoriasis: 1.5 year results from the TRANSFIGURE study. Presented at: The 2017 American Academy of Dermatology Annual Meeting; 2017 March 3–7; Orlando, FL.
   Google Scholar
• Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386:541–551.
   PubMed Web of Science ®Google Scholar
• Dennehy EB, Zhang L, Amato D, et al. Ixekizumab is effective in subjects with moderate to severe plaque psoriasis with significant nail involvement: results from UNCOVER 3. J Drugs Dermatol. 2016;15:958–961.
   PubMed Web of Science ®Google Scholar
• Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49.
   PubMed Web of Science ®Google Scholar
• Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74:134–142.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76:405–417.
   PubMed Web of Science ®Google Scholar
• Mease P, van der Heijde D, Landewé R, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018;77:890–897.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Fleischmann R, Wollenhaupt J, et al. Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol. Ann Rheum Dis. 2014;73:233–237.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Van den Bosch F, Sieper J, et al. Performance of 3 ethesitis indices in patients with peripheral spondyloarthritis during treatment with adalimumab. J Rheumatol. 2017;44:599–608.
   PubMed Web of Science ®Google Scholar
• McGonagle D, Tan AL, Benjamin M. The nail as a musculoskeletal appendage-implications for an improved understanding of the link between psoriasis and arthritis. Dermatology. 2009;218:97–102.
   PubMed Web of Science ®Google Scholar
• McInnes IB, Mease PJ, Kirkham B, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386:1137–1146.
   PubMed Web of Science ®Google Scholar